Enhance Skin Products Inc

Q: Jan 31 2017

Q: Jan 31 2017

Q: Oct 31 2016

Q: Jul 31 2016

FY: Apr 30 2016

Q: Jan 31 2016

Q: Oct 31 2015

Q: Oct 31 2015

Q: Oct 31 2015

Q: Jul 31 2015

FY: Apr 30 2015

Q: Jan 31 2015

Q: Jan 31 2015

FY: Apr 30 2014

FY: Apr 30 2014

Q: Oct 31 2014

Q: Oct 31 2014

Q: Jul 31 2014

FY: Apr 30 2014

Q: Jan 31 2014

8.01

2.01,3.02

4.01,9.01

1.01,8.01,9.01

1.01,9.01

1.01,9.01

1.01,9.01

1.01,9.01

1.01,9.01

1.01,9.01

1.01,9.01

1.01,9.01

1.01,2.03,9.01

1.01,2.03,3.02,9.01

1.01,2.03,3.02,9.01

Unregistered Sales of Equity Securities

Entry into a Material Definitive Agreement

1.01,2.03,3.02,9.01

1.01,2.03,3.02,9.01

8.01,9.01

Certification of termination of registration of a class of securities (Section 12(g))

06b

06

Notice of Effectiveness

Amended Initial Registration Statement

Registration (IPO) statement under Securities Act of 1933

No description available

Notice of Effectiveness

No description available

No description available

No description available

No description available

No description available

No description available

No description available

No description available

No description available

Asculai Samuel

Botnevik Frode

Puseljic Drasko

Nicholson Donald

none

Botnevik Frode

Asculai Samuel

Asculai Samuel

Nicholson Donald

Crisnic Fund, S.A.

Biostrategies Consulting Group Inc

Asculai Samuel

Puseljic Drasko

Nicholson Donald

Noon Zenas B.

Botnevik Frode

Nicholson Donald

Enhance Skin Products Inc.

Hovey Christopher

Enhance Skin Products Inc.

Definitive information statement

Definitive information statement

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Definitive information statement

Definitive information statement

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC